Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder Predominantly Due to Alzheimer's Disease

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Sep 13, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a new computer-based tool called CogCheck, designed to assess cognitive abilities in patients with mild or major neurocognitive disorders, mainly due to Alzheimer's disease. The goal is to see how accurately CogCheck can identify cognitive impairment compared to traditional paper-and-pencil tests. Researchers believe that using a computerized test can make it easier and quicker to evaluate brain function, leading to early and accurate diagnosis of conditions like dementia.

To participate in the trial, individuals must be at least 65 years old, have completed at least seven years of education, and be fluent in German. They should also have undergone a neuropsychological assessment recently that suggests cognitive impairment. Participants will take the CogCheck test on an iPad, which is designed to be user-friendly. The study is currently looking for volunteers, and by joining, participants can contribute to improving how cognitive disorders are diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥65 years
• • 2. Education ≥7 years
• • 3. Fluency in the German language
• • 4. Completed neuropsychological assessment (max. 3 months before data collection of CogCheck)
• • 5. Informed consent signed
• • 6. Clinical course based on caregiver information and neuropsychological assessment profile strongly suggest mild or major NCD predominantly due to AD.
• Exclusion Criteria:
• • 1. Severe sensory (e.g. auditory, visual) or motor impairment (e.g. essential tremor, paresis, dyskinesia) interfering with cognitive testing
• • 2. MMSE score ≤20/30 or MoCA ≤12/30.